An Unexpected Result in Pancreatic Cancer: Nab-Paclitaxel and Gemcitabine Instead of mFOLFIRINOX
In this article
📌 Why Does It Matter?
Pancreatic canceris one of the solid tumors with the poorest prognosis, with more than 80% of patients having metastatic or surgically unresectable disease at diagnosis. The disease often progresses silently, and treatment options are limited when it is discovered at an advanced stage.
For the past 10 years, mFOLFIRINOX and nab-paclitaxel + gemcitabine have been considered, for metastatic patients with good performance status (ECOG 0–1), standard first-line treatment combinations.
Until now, however, the two regimens had not been compared directly. The place of the regimen containing the oral fluoropyrimidine S-1, frequently used in Asian countries, S-IROX , was also unclear in this comparison.
On July 28, 2025, Journal of Clinical Oncologypublished the GENERATE, JCOG1611 trial, filling an important gap in the literature by comparing all three regimens within the same randomized design in this study.
Study Design
- Number of patients: 527 (45 centers in Japan)
- Study period: April 2019 – March 2023
- Randomization: In a 1:1:1 ratio
- Arms:
- mFOLFIRINOX – Modified doses of 5-FU, leucovorin, irinotecan and oxaliplatin
- S-IROX – Oral S-1 + irinotecan + oxaliplatin
- Nab-paclitaxel + gemcitabine
- Primary endpoint: Overall survival (OS)
- Eligibility criteria: ECOG PS 0–1, age 20–75, histologically confirmed metastatic or recurrent pancreatic adenocarcinoma
⏱ Results (Interim Analysis – Early Stopping)
At interim analysis, GENERATE (JCOG1611) showed that the probability of mFOLFIRINOX or S-IROX being superior to nab-paclitaxel + gemcitabine was <1%, which led to early termination for “futility.”
Statistically, this meant that a significant difference was very unlikely to emerge later.
The trial therefore closed ahead of schedule to avoid unnecessarily exposing patients to more toxic treatment.
Contrary to expectations, nab-paclitaxel + gemcitabine produced the best median overall survival.
| Treatment Group | Median Overall Survival (months) | HR (Reference: Nab-paclitaxel + Gemcitabine) |
|---|---|---|
| Nab-paclitaxel + Gemcitabine | 17.1 | — |
| mFOLFIRINOX | 14.0 | 1.31 (0.97–1.77) |
| S-IROX | 13.6 | 1.35 (1.00–1.82) |
- PFS (progression-free survival): Similar across all arms (~6–7 months)
- ORR (objective response rate):
- Nab-paclitaxel + gemcitabine: 35.4%
- mFOLFIRINOX: 32.4%
- S-IROX: 42.4% (highest response rate despite no overall survival advantage)
🔎 Subgroup Analysis – GENERATE (JCOG1611)
What Are We Seeing? The forest plot below summarizes how mFOLFIRINOX and S-IROX performed compared with nab-paclitaxel + gemcitabine in terms of overall survival across subgroups.
HR < 1 → Against nab-paclitaxel + gemcitabine; HR > 1 → Against the comparator treatment. 95% CI not crossing 1 means the difference is statistically significant.
🌟 Notable Subgroups (Statistically Significant Differences)
- Age ≥ 65 — Nab-paclitaxel + gemcitabine superior
- ECOG 0 — Nab-paclitaxel + gemcitabine superior
- Two metastatic sites — Nab-paclitaxel + gemcitabine markedly superior
⚠️ Side Effect Profile
Side effects differed enough to directly influence treatment selection:
- Nab-paclitaxel + gemcitabine: Grade 3–4 neutropenia 60.3%; anorexia 5.2%; diarrhea 1.1%
- mFOLFIRINOX: Anorexia 22.8%; diarrhea 8.8%; febrile neutropenia 8.8%
- S-IROX: Anorexia 27.6%; diarrhea 23.0% (markedly high)
💡 Why Did Nab-Paclitaxel + Gemcitabine Stand Out?
- Second-line treatment advantage: After nab-paclitaxel + gemcitabine, continuation with liposomal irinotecan was possible → longer PPS (post-progression survival)
- Better tolerability: Treatment interruptions due to toxicity were more common in the mFOLFIRINOX/S-IROX arms
- Patient profile: In GENERATE, 67% had PS 0 and 60% had a single metastatic site → an already favorable-prognosis group
🌏 Clinical Messages
- In Asian populations, nab-paclitaxel + gemcitabine may be as effective as mFOLFIRINOX and may even provide an overall survival advantage
- Toxicity management is critical; aggressive chemotherapy may not always mean longer life
- Biomarker-based selection (e.g., BRCA1/2 mutation) matters; choosing the “strongest” chemotherapy without it is not always right
- mFOLFIRINOX/S-IROX remains an important option for patients with BRCA mutations or platinum-sensitive disease
Sources
DOI:10.1200/JCO.24.00936
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.